Patents Issued in December 17, 2024
  • Patent number: 12168643
    Abstract: The present disclosure relates to compounds of Formula I: suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 17, 2024
    Assignee: NMD PHARMA A/S
    Inventors: Nicholas Kelly, Lars J.S. Knutsen, Daniel Paul Cotton
  • Patent number: 12168644
    Abstract: The present invention relates to a method for preparing 2-alkoxy-4-amino-5-methylpyridines of the formula (I) and/or 2-alkoxy-4-alkylamino-5-methylpyridines of the formula (II) from the corresponding 2-haloaminopyridines and the appropriate alcohols in the presence of base, and to the compounds resulting therefrom.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: December 17, 2024
    Assignee: Saltigo GmbH
    Inventor: Karsten von dem Bruch
  • Patent number: 12168645
    Abstract: Provided are a phenanthroimidazole derivative, and a preparation method therefor, and an application thereof. The phenanthroimidazole derivative has a structural formula as shown in Formula (I), R being an electron donor group, wherein by taking a phenanthroimidazole group containing a trifluoromethyl phenyl group as an electron acceptor, and in virtue of the properties of the specific electron donor group R, the phenanthroimidazole derivative containing a light-absorbing photosensitive group of a series D-?-A structure is synthesized, and can be used as a photoinitiator, which is used in the technical field of UV light-curing systems or 3D printing.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: December 17, 2024
    Assignee: GUANGDONG UNIVERSITY OF TECHNOLOGY
    Inventors: Yanping Huo, Yudong Wen, Hongping Xiang, Shaomin Ji, Wencheng Chen, Jiye Luo, Liang Gao, Jingwei Zhao
  • Patent number: 12168646
    Abstract: The present invention relates to pharmaceutical compounds of Formula (I): as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of aryl hydrocarbon receptor (AhR) and to treat conditions comprising inflammation inside the intestinal tract and certain disorders of the central nervous system affected by the gut-brain axis, including IBD, ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.
    Type: Grant
    Filed: February 5, 2024
    Date of Patent: December 17, 2024
    Assignee: NEXYS THERAPEUTICS, INC.
    Inventors: Tom Yao-Hsiang Wu, Qihui Jin
  • Patent number: 12168647
    Abstract: Described herein are compounds according to Formula (I) wherein Rf is a perfluorinated divalent group comprising 2 to 12 carbon atoms; and Z is selected from —CH?CH2, and —CH2CH?CH. A method of making the compound from a functionalized vinyl ether and ammonia is disclosed. In one embodiment, the functionalized triazine-containing compound is used in the polymerization of a fluoropolymer. In another embodiment, the functionalized triazine-containing compound is used in a curable fluoropolymer composition and cured to form articles.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: December 17, 2024
    Assignee: 3M Innovative Properties Company
    Inventors: Michael H. Mitchell, Tatsuo Fukushi, Miguel A. Guerra, Zai-Ming Qiu, Justin T. Roop
  • Patent number: 12168648
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: December 17, 2024
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Alok Nerurkar, Corinne Sadlowski, Frederick Seidl, Heng Cheng, Jason Duquette, John Lee, Martin Holan, Pingyu Ding, Xiaodong Wang, Tien Widjaja, Thomas Nguyen, Ulhas Bhatt, Yihong Li, Zhi-liang Wei
  • Patent number: 12168649
    Abstract: The present invention relates to a process for the production of chromanol and 2-methyl-1,4-naphthoquinone derivatives, more specifically to a process for preparing a compound of the general formula (I) or (II) wherein the variables are as defined in the claims and the description.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: December 17, 2024
    Assignee: BASF SE
    Inventors: Melanie Weingarten, Wolfgang Siegel, Michael Puhl
  • Patent number: 12168650
    Abstract: This disclosure provides crystalline forms of an androgen receptor modulator, and methods of making and using these forms.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: December 17, 2024
    Assignee: NIDO BIOSCIENCES, INC.
    Inventors: Bakary-Barry Toure, Magnus Ronn
  • Patent number: 12168651
    Abstract: An 9-(6-flouro-2-hydroxypyridin-3-yl)-10-(2-hydroxyethyl)-3,6-diphenyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: January 29, 2024
    Date of Patent: December 17, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 12168652
    Abstract: Disclosed herein are carborane derivatives of Formula I or Formula V, or a pharmaceutically acceptable salt thereof, for use as neuromuscular blocking agents. The carborane is substituted with two cationic functional groups selected from amines that form ammonium cations, ethers and/or alcohols that form oxonium cations, sulfides and/or thiols that form sulfonium cations, and phosphanes and/or phosphines that form phosphonium cations.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: December 17, 2024
    Assignee: The Curators of the University of Missouri
    Inventors: George R. Kracke, Lalit N. Goswami, Marion F Hawthorne, Satish S. Jalisatgi
  • Patent number: 12168653
    Abstract: The present invention relates to compounds of formula (I): (I) wherein Q is selected from O or S; R1 is an optionally substituted hydrocarbyl group which may optionally include one or more heteroatoms N, O or S in its carbon skeleton, provided that the hydrocarbyl group includes at least one heteroatom N, O or S in its carbon skeleton or is substituted with a substituent comprising at least one heteroatom N, O or S, and provided that the atom of R1 which is attached to the sulfur atom of the remainder of the molecule is not a ring atom of a cyclic group; R2 is an ?,??-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHRs or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 17, 2024
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Jimmy Van Wiltenburg, Jonathan Shannon, Stephen St-Gallay
  • Patent number: 12168654
    Abstract: The present invention discloses a pyrimidine derivative containing one deuterium atom, a preparation process thereof and a use thereof. It is demonstrated through in vivo and in vitro animal experiments that the antitumor activity of the pyrimidine derivative containing one deuterium atom provided in the disclosure is significantly superior to that of the positive drug Tepotinib, and the preparation process is simple and low in cost.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: December 17, 2024
    Assignees: Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong CS-Lewwin Drug Research Co., Ltd.
    Inventors: Xingshu Li, Xinzi Chen, Wei Yang, Jianmin Guo
  • Patent number: 12168655
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: December 17, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wei Meng, Hannguang J. Chao, Heather Finlay, R. Michael Lawrence, Michael C. Myers
  • Patent number: 12168656
    Abstract: A process for making (E)-7-(4-((5-(2-chlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound The process including: stirring a solution of 5-(2-chlorobenzylideneamino)-1,3,4-thiadiazole-2(3H)-thione and formaldehyde in ethanol to obtain a reaction mixture; adding ciprofloxacin HCl and triethylamine to the reaction mixture and stirring with reflux; cooling the reaction mixture at room temperature to obtain a solid; and obtaining the 7-(4-((5-(2-chlorobenzylideneamino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid compound. Its use as an anticancer and/or anti-inflammatory agent.
    Type: Grant
    Filed: February 6, 2024
    Date of Patent: December 17, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 12168657
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: December 17, 2024
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventors: Stéphane Dorich, Amandine Chefson
  • Patent number: 12168658
    Abstract: Provided are compounds, compositions and methods for inhibiting fascin activity or treating a condition or disorder mediated by fascin activity in a subject in need thereof.
    Type: Grant
    Filed: December 21, 2023
    Date of Patent: December 17, 2024
    Assignees: NOVITA PHARMACEUTICALS, INC., CORNELL UNIVERSITY
    Inventors: Xin-Yun Huang, Christy Young Shue
  • Patent number: 12168659
    Abstract: A thioamide derivative of formula (I) and a preparation method thereof: An application of the thioamide derivative, or an isomer, a pharmaceutically-acceptable salt, or a prodrug molecule thereof in the preparation of a drug for the treatment of cancer is also provided. The thioamide derivative is a new compound with high antitumor activity, and can be used for antitumor therapy alone or in combination with other drugs.
    Type: Grant
    Filed: April 25, 2024
    Date of Patent: December 17, 2024
    Assignee: Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd.
    Inventors: Zhengwu Shen, Bin Deng, Mengqi Zhang, Hongzhu Bian
  • Patent number: 12168660
    Abstract: The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: December 17, 2024
    Assignee: Incyte Corporation
    Inventors: Ming Tao, Jason Boer
  • Patent number: 12168661
    Abstract: A series of novel donor-acceptor type TADF luminogens have been designed with the aim of developing stable OLEDs with enhanced operational stability and improved color purity. These materials can be utilized in full color displays and lighting applications.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: December 17, 2024
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Jian Li, Xinqiang Tan
  • Patent number: 12168662
    Abstract: Novel pyrido[4?,3?:4,5]pyrrolo[2,3-c][2,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[4?,3?:4,5]pyrrolo[2,3-c][2,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 15, 2023
    Date of Patent: December 17, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 12168663
    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: December 17, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Yanke Liang, Tinghu Zhang, Nicholas Paul Kwiatkowski
  • Patent number: 12168664
    Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3, C1-C4 alkyl, aryl or heteroaryl; X is N or CR6, wherein R6 is H, OH, or halogen; A is absent or present, and when present is B has the structure: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: December 17, 2024
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Konstantin Petrukhin, Kirsten Alison Rinderspacher, Shi-Xian Deng, Andras Varadi, Boglarka Racz, Peter Bernstein, Patricia C. Weber, Donald W. Landry, Andrew S. Wasmuth
  • Patent number: 12168665
    Abstract: Provided are compounds of formula (I): or a cosmeceutically acceptable or pharmaceutically acceptable salts thereof. Additionally provided are pharmaceutical and/or cosmeceutical compositions and formulations comprising the compounds and/or the cosmeceutically acceptable or pharmaceutically acceptable salts thereof, therapeutic and/or cosmetic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP)/?-catenin mediated signaling in treating skin related diseases, conditions or disorders (e.g., dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP/?-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.) mediated by aberrant CBP/?-catenin signaling.
    Type: Grant
    Filed: April 27, 2023
    Date of Patent: December 17, 2024
    Assignee: Genesis Molecular Technologies, Inc.
    Inventor: Fuqiang Ruan
  • Patent number: 12168666
    Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: December 17, 2024
    Assignee: G1 Therapeutics, Inc.
    Inventors: Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
  • Patent number: 12168667
    Abstract: The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: December 17, 2024
    Assignee: DUALITY BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Yu Zhang, Zhongyuan Zhu, Haiqing Hua, Bing Li, Jian Li, Shengchao Lin, Xi Li, Hongxia Shen
  • Patent number: 12168668
    Abstract: Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: December 17, 2024
    Assignee: SHY Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds
  • Patent number: 12168670
    Abstract: Embodiments of the present invention provide a method, comprising obtaining a lecithin-containing material, in some aspects derived from a crude refining stream, comprising 20-80 wt % acetone insoluble matter, 1-30 wt % free fatty acid, and less than 10 wt % water, adding a fatty acid or carboxylic source to the lecithin-containing material to obtain a lecithin fatty acid blend or lecithin carboxylic acid blend and incorporating the blend into asphalt or oil field applications.
    Type: Grant
    Filed: October 19, 2023
    Date of Patent: December 17, 2024
    Assignee: CARGILL, INCORPORATED
    Inventors: Todd L. Kurth, Suzanne Stauduhar, Hassan Ali Tabatabaee
  • Patent number: 12168671
    Abstract: Provided are phosphonopyrazole-based phosphohistidine analogs that are useful as haptens for the preparation of immunogens, immunogens that include these haptens linked to carrier molecules, antibodies thereto and uses of these antibodies, haptens, immunogens and phosphohistidine analogs.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: December 17, 2024
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Tom W. Muir, Rob C. Oslund, Jung-Min Kee
  • Patent number: 12168672
    Abstract: Processed lignin comprising the elements carbon (C), hydrogen (H) and oxygen (O) in the following amounts: C in an amount of between 60 and 85% by weight, H in an amount of between 3.0 and 6.0% by weight, O in an amount of between 10 and 29% by weight, wherein the weight ratio C/H is at least 12.5, the ratio C/O is at least 2.5, the processed lignin comprises less than 0.1% by weight of total CI, a sulphur content below 1 g/kg, and a moisture content less than 3% by weight. A process to prepare the processed lignin comprising subjecting particles comprising lignin and cellulose and optionally hemicellulose to acidic hydrolysis using hydrochloric acid of at least 35%, subjecting the obtained residue to a high temperature treatment of between 300 and 500° C. under inert gaseous atmosphere to a total CI level of below 0.1% by weight, after drying.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: December 17, 2024
    Assignee: Avantium Knowledge Centre B.V.
    Inventors: Anna Louise Jongerius, Scott Henry Russell, Kay Jochem Damen, Benjamin McKay
  • Patent number: 12168673
    Abstract: Prodrugs of nicotinic acid which include ribosyl groups are provided. The compounds and pharmaceutical compositions thereof may be used to treat or prevent to treat or prevent a variety of medical disorders, which are characterized by mitochondrial dysfunction such as, for example, metabolic disorders, cardiovascular disorders, cerebrovascular disorders, liver disorders, kidney disorders or muscle disorders.
    Type: Grant
    Filed: March 2, 2023
    Date of Patent: December 17, 2024
    Assignee: Mitopower, Inc.
    Inventors: G. Mani Subramanian, Gangadhara Ganapati, Manoj Chandrasinhji Desai, Nikhil Saji Zachariah, Ajay Kumar K S, Gautham Tumkur Pranesh
  • Patent number: 12168674
    Abstract: The present disclosure provides reagent compounds, reactive biopolymeric compounds, and methods of making and using these materials for the rapid and efficient synthesis and purification of biopolymeric compounds at low cost. The materials and methods yield highly pure synthetic biopolymeric compounds, including synthetic oligonucleotides and polypeptides, and reduce or eliminate the need for toxic solvents in the synthetic process.
    Type: Grant
    Filed: December 8, 2023
    Date of Patent: December 17, 2024
    Assignee: Oligo Foundry, Inc.
    Inventors: David A. Schwartz, Jimmy H. Williams
  • Patent number: 12168675
    Abstract: The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.
    Type: Grant
    Filed: June 7, 2023
    Date of Patent: December 17, 2024
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gary J. Nabel, Srinivas Rao, Wataru Akahata
  • Patent number: 12168676
    Abstract: The disclosure provides therapeutic peptides and pharmaceutical compositions comprising the peptides, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic peptides are useful as immunotherapeutics for modulating regulatory and effector molecules of the mammalian immune system to mitigate disease.
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: December 17, 2024
    Assignee: Genevive, Inc.
    Inventors: Yuliya Katlinskaya, Helena Kiefel, Kareem L. Graham, Todd Z. DeSantis, Sunit Jain, Andrew W. Han, Karim Dabbagh
  • Patent number: 12168677
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: July 18, 2023
    Date of Patent: December 17, 2024
    Assignee: Genevive, Inc.
    Inventors: Andrew Wonhee Han, Andrew W. Goodyear, Tarunmeet Gujral, Todd Zachary DeSantis, Karim Dabbagh
  • Patent number: 12168678
    Abstract: The disclosure relates to engineered heme sequestering peptides and their use in treating cancer and inhibiting microbial infections and colonization.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: December 17, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Li Zhang
  • Patent number: 12168679
    Abstract: The present disclosure relates generally to modified bacteria, such as E. coli, with modification in the expression of at least one gene encoding a type I and/or type II toxin-antitoxin (TA) system protein and/or at least one gene encoding a structural protein that modulates ribosomes and methods of using the disclosed bacteria for producing a biological compound of interest. The modifications of the bacteria result in enhanced bioproduction.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: December 17, 2024
    Assignee: Northwestern University
    Inventors: William H. Bothfeld, Keith E. J. Tyo
  • Patent number: 12168680
    Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
    Type: Grant
    Filed: April 24, 2023
    Date of Patent: December 17, 2024
    Assignee: Altor Bioscience, LLC
    Inventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-Ping Han
  • Patent number: 12168681
    Abstract: This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R?. The IL-2 variants may retain the ability in binding to or activating IL-2R? and/or IL-2R?. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: December 17, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi Wu, Tong Zhang, Samuel Davis, Nicolin Bloch
  • Patent number: 12168682
    Abstract: The specification describes an antibody capture process comprising (i) obtaining a biological sample comprising antibodies, (ii) contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex. The process may further comprise (iii) directly or indirectly assessing the level of the pIgR-dIgA complex or the level of a complex between pIgR-dIgA and an antigen of interest. There is also an antibody capture process for determining gut wall integrity in a test subject, wherein the level or ratio of SIgA to dIgA is compared to a corresponding level or ratio from a control subject. The specification provides kits embodying the process and recombinant pIgR when used for, or for use, in capturing or detecting dIgA and/or IgM.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: December 17, 2024
    Assignee: The MacFarlane Burnet Institute for Medical Research and Public Health Ltd
    Inventors: David Andrew Anderson, Mary Louise Garcia, Nadine Carmel Barnes, Khayriyyah Mohd Hanafiah, Alan Lee Landay
  • Patent number: 12168683
    Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIB:T?RII heteromultimers comprising an ActRIIB polypeptide and a T?RII polypeptide). In some embodiments, the disclosure provides for novel binders comprising a T?RII polypeptide and a heterologous portion. The disclosure further provides that such multispecific binders (e.g., ActRIIB:T?RII heteromultimer) may be used to treat various disorders or conditions.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: December 17, 2024
    Assignee: Acceleron Pharma Inc.
    Inventors: Ravindra Kumar, Dianne S. Sako, Roselyne Castonguay, Tzu-Hsing Kuo
  • Patent number: 12168684
    Abstract: The present invention relates to the preparation of an antibody analogue capable of being activated reversibly, and uses thereof, and provides a fusion protein comprising an inactive first fragment of an antibody analogue is fused to a stimulus-induced dimerization protein.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: December 17, 2024
    Assignee: INSTITUTE FOR BASIC SCIENCE
    Inventors: Won Do Heo, Yun Ju Lee, Daseuli Yu, Byung Ouk Park
  • Patent number: 12168685
    Abstract: Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.
    Type: Grant
    Filed: October 18, 2022
    Date of Patent: December 17, 2024
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Renata Pasqualini, Wadih Arap, Fernanda Iamassaki Staquicini, Fortunato Ferrara, Sara D'Angelo, Andrew R. M. Bradbury
  • Patent number: 12168686
    Abstract: Compositions of TNF family of cytokines in covalently linked trimeric forms are disclosed. The resulting fusion proteins are secreted as disulfide bond—linked homotrimers, which are more stable in structure and therapeutically more efficacious than their native counterparts.
    Type: Grant
    Filed: October 16, 2022
    Date of Patent: December 17, 2024
    Assignee: Sichuan Clover Biopharmaceuticals, Inc.
    Inventor: Peng Liang
  • Patent number: 12168687
    Abstract: Antibodies and antigen-binding fragments thereof that immunospecifically bind to PD-1, such as human or mouse PD-1, and are agonists of PD-1 and can induce or promote an immune response that activates immune cell proliferation or activity. Unlike the majority of known anti-PD-1 and anti-PD-L1 antibodies, which reduce the suppression of PD-1 function by e.g., PD-L1 by physically blocking the interaction between PD-1 and an inactivating ligand, although not to be bound by theory, the disclosed antibodies and antigen-binding fragments thereof are currently best understood to immunospecifically bind to an epitope of PD-1 whereby PD-1 is activated directly. Methods for the treatment of cancer comprising administration of the antibodies or antigen-binding fragments to a subject in need thereof. Polynucleotides encoding the antibodies or antigen-binding fragments. Host cells comprising the polynucleotides.
    Type: Grant
    Filed: January 26, 2024
    Date of Patent: December 17, 2024
    Assignee: Georgiamune Inc.
    Inventors: Mikayel Mkrtichyan, Samir Khleif
  • Patent number: 12168688
    Abstract: The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 17, 2024
    Assignee: Nanjing Legend Biotech Co., Ltd.
    Inventors: Shuai Yang, Chuan-Chu Chou, Shu Wu, Liusong Yin, Feng Lin
  • Patent number: 12168689
    Abstract: An IgG1 Fc monomer, a preparation method therefor and an application thereof. Causing an Fc dimer of a novel IgG1 Fc monomer sequence for which an antibody IgG1 constant region is modified to become an Fc monomer by means of the modification on a human antibody IgG1 constant region Fc that uses antibody engineering technology, and maintaining an FcRn binding function; the present application has the feature of very low non-specific binding with unrelated proteins, and the main features of the Fc monomer comprise the T366, L368, P395, and K409 positions in a CH3 region of the constant region of the antibody having mutations, and the monomer being highly efficiently expressed in prokaryotic cells; the monomer may bind to FcRn by using a pH-dependent specific binding mode, and has the feature of very low non-specific binding.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: December 17, 2024
    Assignee: Suzhou Forlong Biotechnology Co., Ltd.
    Inventors: Tianlei Ying, Chunyu Wang
  • Patent number: 12168690
    Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: December 17, 2024
    Assignees: ABL BIO INC., YUHAN CORPORATION
    Inventors: Yeryoung Yong, Ui-Jung Jung, Hyejin Chung, Kyeongsu Park, Wonjun Son, Yangsoon Lee, Yeunju Kim, Eunsil Sung, Youngkwang Kim, Youngdon Pak, Minji Park, Jaehyun Eom, Hyoju Choi, Moo Young Song, Na Rae Lee, Young Bong Park, Eun-Jung Lee, Eun-Jung Lee
  • Patent number: 12168691
    Abstract: The present disclosure provides a bispecific antibody comprising an IgG linked to an scFv, wherein the VII domain of the IgG is linked to the VH domain of the scFv, the bispecific antibody binding a human vascular endothelial growth factor (VEGF) family protein and an epidermal growth factor receptor (EGFR) family protein. Further embodiments provide pharmaceutical compositions comprising the bispecific antibody of the embodiments and aspects thereof and a pharmaceutically acceptable carrier. Further embodiments provide various methods of treating cancer in a subject comprising administering a bispecific antibody of the embodiments and aspects thereof to the subject. A further embodiment provides a kit comprising the bispecific antibody.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: December 17, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Zhen Fan, Yang Lu, Songho Qiu
  • Patent number: 12168692
    Abstract: The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: December 17, 2024
    Assignee: Granite Bio AG
    Inventor: Matthias Mack
  • Patent number: 12168693
    Abstract: The present invention relates to treatments of conditions ameliorated by stimulation of an immune response, in particular by the stimulation of antigen-specific T-lymphocytes. Treatment of such conditions according to the invention is effected by the combination of an anti-human CD27 agonistic antibody together with a number of immune checkpoint inhibitors.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: December 17, 2024
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas